ReviewOpen life sciences2024
Mesoporous silica nanoparticles as a drug delivery mechanism.
Review in Open life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood-Brain Barrier for Advanced Theranostics.AAPS PharmSciTech · 2026Review
- Magnetothermally Responsive Mesoporous Silica Nanocarriers: Materials Design, Thermoresponsive Gates and Controlled Drug Release.Nanomaterials (Basel, Switzerland) · 2026Review
- Folic acid-loaded amino-functionalized MCM-41 as a drug delivery system for cervical cancer modulating apoptotic and survival signals.Scientific reports · 2026Article
- Melatonin rhythm-mimicking smart hydrogel for circadian clock regulation and promotion of intervertebral disc regeneration.Materials today. Bio · 2026Article
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Cardioprotective effects of hesperidin-loaded biodegradable mesoporous copper to reduce cardiomyocyte apoptosis for myocardial infarction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Network Silsesquioxane-Based Organogel/Silicone Composites for the Long-Lasting Delivery of Nitric Oxide.Molecules (Basel, Switzerland) · 2026Article
- Enhancing Therapeutic Efficacy Through Tailored Pharmacokinetics: A Review of Mesoporous Silica Nanoparticle-Based Delivery Systems.International journal of nanomedicine · 2026Review
- Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives.International journal of nanomedicine · 2026Review
- Advances in Mesoporous Silica and Hybrid Nanoparticles for Drug Delivery: Synthesis, Functionalization, and Biomedical Applications.Pharmaceutics · 2025Review
- Engineered mesoporous silica nanosystems with organotin(IV) complexes containing 1-(quinolin-8-yliminomethyl)naphthalen-2-ol ligand for cancer cell targeting.Dalton transactions (Cambridge, England : 2003) · 2025Article
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- Transforming Human Amniotic Membrane into Nanoparticles: An Approach for Cardiac Delivery Systems.ACS applied bio materials · 2025Article
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.International journal of molecular sciences · 2025Review
- Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine.Pharmaceutics · 2025Review
- Synthesis Techniques and Biomedical Applications of Cyclodextrin Metal-organic Frameworks.Current medicinal chemistry · 2025Review
- Regenerative medicine: Hydrogels and mesoporous silica nanoparticles.Materials today. Bio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research in intelligent drug delivery systems within the field of biomedicine promises to enhance drug efficacy at disease sites and reduce associated side effects. Mesoporous silica nanoparticles (MSNs), characterized by their large specific surface area, appropriate pore size, and excellent biocompatibility, have garnered significant attention as one of the most effective carriers for drug delivery. The hydroxyl groups on their surface are active functional groups, facilitating easy functionalization. The installation of controllable molecular machines on the surface of mesoporous silica to construct nanovalves represents a crucial advancement in developing intelligent drug delivery systems (DDSs) and addressing the issue of premature drug release. In this review, we compile several notable and illustrative examples of MSNs and discuss their varied applications in DDSs. These applications span regulated and progressive drug release mechanisms. MSNs hold the potential to enhance drug solubility, improve drug stability, and mitigate drug toxicity, attributable to their ease of functionalization. Furthermore, intelligent hybrid nanomaterials are being developed, featuring programmable properties that react to a broad spectrum of stimuli, including light, pH, enzymes, and redox triggers, through the use of molecular and supramolecular switches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.